l e t t e r s
Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification [1] [2] [3] [4] . We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon a-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.
Biologic medicines, such as recombinantly expressed cytokines, hormones, replacement enzymes, blood factors or antibodies, are routinely used to treat cancer, autoimmune disorders and rare diseases. Increasingly, protein biologics are tailored to small groups of patients based on an understanding of the underlying biology of their disease 5 . The need for small numbers of doses of many products poses a challenge to conventional manufacturers, who produce drugs in large volumes to achieve economies of scale 6 . Furthermore, different classes of biopharmaceuticals (for example, enzymes, hormones, vaccines) generally require unique customized processes for each molecule from expression to purification, constraining commercial facilities to a single class of product.
New technologies to manufacture many different pharmaceuticalquality biologics in small quantities with efficiency and agility are needed to make precision biologic medicines both available and economically feasible 7 . Technologies such as automated laboratory-scale batch processes, in vitro transcription and translation, and microfluidics can rapidly produce limited quantities of different biomolecules on demand [1] [2] [3] [4] . While some of the products generated show biological activity, they lack sufficient quality attributes for clinical use, including identity, purity, safety and potency as required by regulatory agencies. To address this need, we developed an automated multiproduct manufacturing system capable of rapidly producing clinical-grade recombinant proteins and requiring only minimal reconfiguration to make different biopharmaceuticals. Unlike previous solutions, InSCyT comprises fully integrated and automated modules for sustained production, efficient purification of the native protein, and final formulation for parenteral use. The yeast-based production module allows both rapid production of tens to hundreds of doses in under 80 h and sustained production for >100 h of up to thousands of doses as needed, whereas cell-free solutions [1] [2] [3] provide only shortterm expression. The multistage purification module (and associated methods for rapid process development of suitable purification sequences) enables purification of multiple clinical-grade products using highly similar processes without requiring affinity tags that alter the drug sequence and present risks of immunogenicity. In contrast, previous approaches used affinity tags for purification or had no integrated purification step. Finally, the integrated formulation module prepares protein biopharmaceuticals in a final dosage form. These
On-demand manufacturing of clinical-quality biopharmaceuticals l e t t e r s features, combined with the use of integrated design principles to create simplified processes, facilitate the production of recombinant proteins with quality attributes sufficient for clinical use.
We selected Pichia pastoris as our expression host because it can grow quickly to high cell densities and efficiently secrete recombinant proteins 8 . Other advantages of P. pastoris include low levels of secreted host-cell proteins; little to no risk of viral contamination; validated expression of myriad proteins, including therapeutics approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA); and the capability for human-like posttranslational modifications in engineered strains 9, 10 .
InSCyT uses fluidically connected modules for fermentation, multistage chromatography, and ultrafiltration and/or diafiltration, as well as integrated sensors and system controllers for system-wide programmed operations (Fig. 1a,b and Supplementary Fig. 1 ). We implemented continuous fermentation by perfusion to reduce the volume of the bioreactor and enable high space-time yields 11 . To this end, we adapted a sub-liter benchtop bioreactor for in-tank perfusion and equipped it with sensors to control input and output flows, pH, temperature, impeller speed and dissolved oxygen (Fig. 1c) . The bioreactor was connected to a module for inline pH adjustment of the cell culture fluid before chromatographic separations; this module allowed the balancing of flow rates between those for production and purification. An integrated module for purification was designed to enable either two or three stages of chromatographic separation (Fig. 1c) . This module allowed straight-through processing with no intermediate holding tanks or adjustments between purification steps. Our design simplifies the operation of the module relative to traditional purifications, wherein multiple intermediate procedures are often required to adjust pH, conductivity, concentration and composition of fluids between steps of purification. The final module in the system is a tangential flow-filtration system for buffer exchange and formulation to a final liquid dosage form of the product (Fig. 1c) . A custom integrated software architecture unified operation of all three modules with appropriate controls as a fully automated single system.
We built and used three independent InSCyT systems to demonstrate consistent operational performance for both production and purification processes (Fig. 1d,e) . We first produced and purified the common biologic medicine human growth hormone (hGH), used to treat growth deficiencies 12 . The extensive knowledge available about this drug's quality, safety and potency aided our assessment of InSCyT and the novel process we developed for production of hGH. Our production process used two straight-through stages of chromatographic purification and required fewer than half as many operations as the Innovator process (Supplementary Fig. 2 ). We implemented our process on three separate InSCyT systems. After inoculation, each process ran 'hands-free' and produced >100 doses of formulated product in less than 1 week, with initial yields for the process ranging from 27-31% on each system (Fig. 2a) .
We compared the biophysical and biochemical attributes of our purified product from multiple time points on each system to a marketed drug substance using multiple analytics commonly used to establish identity, potency, safety and purity of therapeutic proteins 13 (Fig. 2b,c and Supplementary Fig. 3) . We confirmed the protein sequence (100% coverage) by mass spectrometry (Supplementary Fig. 4) . Potency of InSCyT hGH was comparable to the National Institute for Biological Standards and Control World Health Organization (WHO) 98/574 reference standard (96-104%) using a cell-based proliferation assay. Key contributors to product safety include the levels of potentially immunogenic product-related impurities, such as aggregates, and the presence of process-related impurities, including host-cell proteins (HCPs) and host-cell DNA. Minimal high-molecular-weight species were present in the InSCyT hGH product (<0.5%), and levels of process-related impurities were each below typical values for clinical-stage development (1,000 p.p.m. for HCPs and 10 ng/dose for DNA) [14] [15] [16] . Regulatory agencies usually consider limits for host-cell proteins on a case-by-case basis, although in vitro studies using peripheral blood mononuclear cells from both healthy and diseased individuals have shown that HCP levels up to 4,000 p.p.m. from Chinese hamster ovary (CHO) cells do not pose a higher immunogenicity risk than a highly purified monoclonal antibody (<50 p.p.m.) 15 . A small percentage (average: 6%) of a proteolytically cleaved form of hGH was also observed (two-chain variant); this natural form is both highly potent and previously has been determined as clinically irrelevant 17 . Further assessment for productspecific impurities by tandem liquid chromatography/mass spectrometry (LC-MS), however, showed that InSCyT hGH was not comparable to marketed products because of increased levels of deamidation and oxidation ( Fig. 2c and Supplementary Fig. 5 ).
Given the consistency of both the operation of individual InSCyT systems and the hGH products produced by each system, we attributed the deamidation and oxidation observed in our product to process parameters, rather than the InSCyT system specifically. We therefore modified our process for hGH without any significant hardware changes by changing to a defined cultivation medium, adjusting the set point for dissolved oxygen and eliminating agitation in the surge tank. Using this adjusted process, a single InSCyT system produced nearly 50 maximum weight-based doses of hGH in 75 h (Supplementary Fig. 6 ). Oxidation and deamidation were reduced to below 1% at each residue, while all other quality attributes were maintained (Fig. 2c,d and Supplementary  Fig. 6 ). Process yield also increased to nearly 80%. Together, these data demonstrate the capability of our manufacturing system to rapidly and reproducibly produce tens of doses of a potent and pure form of a biologic drug in an automated, short production cycle.
We next sought to demonstrate on-demand production of hGH. The upstream perfusion process was operated fully automated for 240 h. In addition to the initial purification and formulation cycle on day 3 (described above), two more cycles of purification and formulation were performed on demand during days 6 and 10 ( Supplementary Fig. 6 ). Each on-demand cycle produced between 50 and 75 doses of hGH within 12 h, with product quality and yields similar to those of the batch produced on day 3 (Fig. 2c,d and Supplementary Fig. 6 ). (We attributed the reduced yield (50%) and increased host-cell protein levels observed during the day 6 cycle to overloading the capture column, which we adjusted before the day 10 cycle.) Further optimization of the process and column sizing could improve the consistency from batch to batch. Nonetheless, the ability to produce small lots of this product on demand shows the potential for manufacturing medicines as needed and highlights the stability of yeast-based bioprocesses in continuous operations.
Biopharmaceuticals typically require custom manufacturing processes that vary widely, especially for proteins other than monoclonal antibodies, and require unique facility designs 11 . This constraint limits facility flexibility to provide additional products, which would be essential for on-demand supply. We therefore assessed whether our modular manufacturing system and choice of host could readily produce other molecules with no substantial hardware alterations. We selected interferon-α (IFN-α)-2b as a second example. This potent 19.2-kDa cytokine is used in both monotherapies and drug combinations to treat cancer and hepatitis, and is produced commercially in a specialized 13-step process using E. coli 18 (Supplementary Fig. 2 ). Owing to the ease of targeted transgene insertion and simplicity of upstream process development in P. pastoris, we developed a draft fermentation process for producing secreted IFNα-2b less than 4 weeks l e t t e r s l e t t e r s after identifying the product sequence (Fig. 3a) . We have found that P. pastoris routinely secretes a consistent set of host-cell proteins along with the heterologous product during fermentation to yield a high level of initially pure product (>80%) 19 . This feature made it possible to develop an in silico tool to predict draft multistage purification processes 20 . With this in silico tool, we selected a process to purify IFNα-2b within another 4 weeks. The procedures developed for both production and purification did not require modifications to the InSCyT system itself.
Initial biophysical analyses of IFNα-2b produced in our first run on the InSCyT system indicated minimal high molecular weight species (0.34%) and process-related impurities below typical values for clinical development (Fig. 3c) . A cell-based viral replication assay demonstrated that the potency of our IFNα-2b was the same as or greater than that of a reference drug substance. InSCyT-generated IFNα-2b was highly potent (134%) in part owing to a naturally occurring C-terminal truncation known to increase potency 21 . Assessment for purity by LC-MS and reversed-phase liquid chromatography (RPLC), however, showed that our product quality was not sufficient due to the presence of oxidized forms that could potentially promote aggregation and immunogenicity 22 (Fig. 3c) . These data show that rapid production of biomolecules with acceptable bioactivity is necessary, but not sufficient, to define a clinical-quality biologic product.
To address these attributes, we optimized process conditions on InSCyT, performing experiments on individual modules simultaneously with fully integrated experiments comprising connected modules ( Fig. 3a and Supplementary Fig. 7 ). After 27 d of process development, a final run showed that oxidation was reduced to <1.5% at all residues (Fig. 3b,c) . During this run the system produced nearly 8,000 formulated doses of IFNα-2b in less than 1 week (Supplementary Fig. 8 ). The identity and purity of the product was confirmed by multiple analytical methods at four time points during the campaign ( Fig. 3c and Supplementary Fig. 8 ). RPLC, size exclusion chromatography and LC-MS showed levels of purity within targeted specifications; other analytics showed the specifications for safety and potency of our product were also achieved. Differences in chromatographic behavior of our product were confirmed by matrixassisted laser desorption and ionization mass spectrometry as the naturally occurring C-terminal truncation mentioned previously 21 ( Supplementary Fig. 8 ). The low overall process yield (~11%) is attributed to removal of an N-terminal product variant, which arises as a result of incomplete cleavage of the secretion leader sequence during expression by our host. Further engineering of the expression vector with alternative signal sequences could alleviate the expression of this variant 23 .
Next we produced granulocyte colony stimulating factor (G-CSF), used to stimulate blood cell proliferation and reduce infections in cancer patients treated with myelosuppressive chemotherapy 24 . This drug has manufacturing challenges due to complex folding and a propensity for aggregation and oxidation at specific amino acid residues 25, 26 . We designed a new process for production of G-CSF and implemented it on three InSCyT systems (Supplementary Fig. 2 ). After inoculation, each automated process yielded more than 165 doses of formulated drug in less than 100 h ( Fig. 4a and Supplementary Fig. 9 ). Typical process yields for each cycle ranged from 70 to 90% (average 77%). We assessed biophysical and biochemical attributes of the product using multiple analytics to establish its identity, purity, safety and potency ( Fig. 4a and Supplementary Fig. 9 ). InSCyT G-CSF was comparable to a drug substance from a licensed product. We confirmed the protein sequence (100% coverage) by mass spectrometry ( Supplementary  Fig. 10 ). Minimal high-molecular-weight species were present in the product (0.33-0.65%). Levels of process-related contaminants in our formulated G-CSF were each below values typical for early-stage clinical development (1,000 p.p.m. for HCPs and 100 pg/dose for DNA) [14] [15] [16] . Potency of the InSCyT G-CSF was comparable to that of the NIBSC WHO 09/136 reference standard (89.6-141.1%) in a cell-based proliferation assay. Our product contained a minor variant comprising an N-terminal truncation and was a mixture of aglycosylated and glycosylated forms (Supplementary Fig. 9 ). Neither of these variants are likely to be clinically meaningful, as both truncations and glycosylation have been observed in licensed products without impact on product activity or safety 27, 28 . Overall, these data demonstrate that InSCyT can rapidly and consistently produce therapeutic proteins that are comparable to currently marketed products.
We performed further nonclinical studies with InSCyT-produced G-CSF to provide a framework for future clinical development. We assessed the pharmacokinetics, pharmacodynamics and toxicology of the InSCyT-produced G-CSF by comparing our product to a licensed product (Neupogen) in a rat model. We found InSCyT-produced G-CSF to be comparable to Neupogen in neutrophil activation during a single-dose administration study (Fig. 4b) . InSCyT G-CSF and Neupogen showed no statistically significant difference in pharmacokinetic profile when administered at the same dose (Kolmogorov-Smirnov test, P = 0.9963) (Fig. 4b) . A 5-d repeat-dosing study also showed our product was comparable to Neupogen in toxicity as based on survival, clinical signs, body weight, quantitative food consumption, hematology, serum chemistry, organ weights and macroscopic findings ( Fig. 4b and Supplementary Fig. 11 ). In all these studies, no abnormal signs of toxicity, including injection site inflammation, were observed in any animals dosed with InSCyT G-CSF Figure 2 Production of hGH on the InSCyT system. Dose size used was 1.75 mg (ref. 12) . Center values and error bars represent the mean and range, respectively, of technical triplicates unless otherwise indicated. (a) Process flow chart (left) and timeline and yields (right) for production of hGH using InSCyT. Wet cell weight (black), unpurified (orange) and formulated (blue) doses of hGH produced are shown. Gray circles represent individual data points. (b) Product quality analyses for InSCyT-produced hGH before optimization, alongside a reference drug substance from a licensed hGH product produced in E. coli. SDS-PAGE (12% Tris-glycine) analysis of samples from the USP during biomass accumulation and production (perfusate samples), final formulated samples, and the reference (Std); M, molecular mass marker. Activity of InSCyT hGH alongside the WHO international standard (NIBSC 98/574). The final formulated sample (day 6) was analyzed from each system. Quantification of host-cell protein (HCP) and host-cell DNA impurities in formulated InSCyT hGH. Host-cell protein limits are shown as a target range 14, 15 . Host-cell DNA guidelines are based on 100 pg/dose (FDA) and 10 ng/dose (EMA) 16, 30 . For host-cell protein data, each point represents a unique sample (12 points total: 4 time points from each of three InSCyT systems). For host-cell DNA, each point represents a single pooled sample from each system comprising equal volumes of samples from each time point (3 points total, 1 per system). (c) Analysis of productrelated variants in formulated InSCyT hGH before (top) and after optimization (bottom) alongside levels typically found in marketed products ( Supplementary  Fig. 5 ). Each data point represents a unique sample; there are 12 data points for runs before optimization (four time points from each of three InSCyT systems) and 3 data points for runs after optimization (three time points from a single InSCyT system). Black boxes represent the range of InSCyT hGH samples, with a line at the mean. (d) Product quality analyses for InSCyT-produced hGH after optimization alongside reference drug substance from a licensed hGH product. SDS-PAGE (12% Tris-glycine) analysis of samples from the USP during biomass accumulation and production (perfusate samples), final formulated samples, and the reference (Std). Activity of InSCyT hGH alongside the WHO international standard (NIBSC 98/574). Secondary structure analysis of InSCyT hGH (individual formulated samples from days 3, 6 and 10) and the reference hGH standard using circular dichroism; MRW, mean residue ellipticity. l e t t e r s (58 in total). Together, these data suggest that the InSCyT-produced G-CSF has potency in vivo and that potentially immunogenic process-related impurities are appropriately minimized.
InSCyT can produce a variety of clinical-quality recombinant therapeutic proteins in a liquid dosage form through integrated production, purification and formulation under a single control architecture. The efficient secretion of proteins by P. pastoris, combined with a holistic design of purification sequences, enabled processes for hGH, IFNα-2b and G-CSF that reduced the total number of processing steps by 45% or more and did not require refolding, excursions in pH or other Figure 3 Accelerated process development using the InSCyT system and production of IFNα-2b. Dose size was 12 µg (ref. 18) . Center values and error bars represent the mean and range, respectively, of technical triplicates unless otherwise noted. (a) Process development timeline for new manufacturing processes using the InSCyT system, including simultaneous unit operation development (comprising strain development and purification development), at-scale process development (comprising simultaneous experiments on individual modules and on the fully integrated system) and process qualification. (b) Timeline for at-scale process development for IFNα-2b. Horizontal colored bars represent the modules that were used in each experiment (USP, orange; DSP, purple; TFF, blue). Each new bar represents a new set of experimental conditions on that module. (c) Product quality for InSCyT-produced IFNα-2b from the first at-scale run after initial unit operation development (first at-scale process development run) and the final qualification run alongside a reference drug substance produced in E. coli. SDS-PAGE (12% Tris-glycine) analysis of samples from the USP during production (P), a final formulated sample (F) and a reference drug substance (Std); M, molecular mass marker. Analysis of process-related variants in formulated InSCyT IFNα-2b (per Fig. 2b ). Each data point represents a unique sample, including one data point from the first at-scale process development run and four data points from the qualification run (four time points from a single InSCyT system). Product-related variants detected in formulated InSCyT IFNα-2b alongside levels typically found in a reference drug substance ( Supplementary Fig. 5 ). Black boxes represent the range of InSCyT IFNα-2b samples, with a line at the mean. Secondary structure analysis of InSCyT IFNα-2b (triplicate analyses of an individual sample from the qualification run) and reference drug substance (duplicate analyses of an individual sample) using circular dichroism; MRW, mean residue ellipticity. . Center values and error bars represent the mean and range, respectively, of technical triplicates unless otherwise noted. (a) Timeline and yields for production of G-CSF using the InSCyT system for a single representative sample (batch 1). Wet cell weight (black circles) and cumulative unpurified (orange) and formulated (blue) doses of G-CSF are shown. Gray circles represent individual data points. Product quality for InSCyT-produced G-CSF alongside drug substance from a licensed product produced in E. coli and Neupogen (produced by Amgen in E. coli). A photograph of vials comparing material sampled from the USP (perfusate) to final formulated material (formulated). SDS-PAGE (12% Tris-glycine) analysis of batch 1 from the USP during biomass accumulation (G) and production (P), and a final formulated InSCyT sample (F) alongside drug substance from a licensed product (Std); M, molecular mass marker. Analysis of product purity by isoelectric focusing (IEF) for formulated batch 1. Gel analyses of batch 1 are representative of all six batches ( Supplementary Fig. 9 ). Analysis of product-related variants and process-related variants. Each data point represents a unique batch (two time points from each of three distinct systems). Paired data points indicate analyses from a single batch. Product-related variants are shown alongside levels typically found in marketed products ( Supplementary Fig. 5 ). Black boxes represent the range of InSCyT G-CSF samples, with a line at the mean. Process-related variants are shown alongside common guidelines (per Fig. 2b) . Analysis of the secondary structures of InSCyT G-CSF (batches 1-6) and a reference drug substance from a licensed product using circular dichroism. Activity of InSCyT G-CSF alongside that of the WHO international standard (NIBSC 09/136). (b) Analysis of pharmacokinetics, pharmacodynamics and toxicology of InSCyT-produced G-CSF and a licensed product (Neupogen) in a rat model. Neutrophil activation and pharmacokinetic profile of low dose (115 µg/kg, n = 3 animals, t 1/2 = 2.1 h) and high dose (575 µg/kg, n = 3 animals, t 1/2 = 4.6 h) InSCyT G-CSF in rats compared to Neupogen (115 µg/kg, n = 3 animals, t 1/2 = 1.4 h) (pharmacokinetics: P = 0.9963, Kolmogorov-Smirnov test). For neutrophil activation, gray boxes represent the range of three individual animals, with a line at the mean. For pharmacokinetics, center points and error bars represent the mean and range, respectively, of three individual animals. Summary of statistically significant results comparing the toxicology of InSCyT G-CSF and Neupogen to a vehicle control. Values represent the mean; s.d. and sample size can be found in Supplementary Figure 11 . Statistical significance was determined by one-way ANOVA. ALP, alkaline phosphatase; MRW, mean residue ellipticity; M, male; F, female. l e t t e r s substantial changes to the protein itself during processing (Supplementary Fig. 2) . We demonstrated fast cycles of process development to reach clinically relevant target specifications in 12 weeks, aided by testing production at scale in a modular and integrated manner on InSCyT. The combination of the manufacturing system with the demonstrated strategy for process development could facilitate the rapid transition of lead molecules into the clinic for translational studies and reduce subsequent iterations in process development and technology transfer for late-stage and commercial manufacturing.
Further engineering of InSCyT to comply with current good-manufacturing practices and concurrent development of an appropriate control strategy would enable its use for chemistry, manufacturing and controls of new drugs. A fill and finish module would enable product vial dispensing for simple administration to patients. Several relevant solutions have emerged, including systems from MedInstill and Vanrx. Modular facilities for housing manufacturing equipment, such as G-Con PODs and Germfree BioGO Modules, also are becoming widely available for aseptic containment of small-scale manufacturing facilities.
InSCyT could be used in its current form to produce many other products, such as monoclonal antibodies, vaccine components, nanobodies and other antibody-like proteins (for example, bispecific T-cell engagers, Fabs), blood products (such as erythropoietin) and therapeutic enzymes (for example, β-glucocerebrosidase). Other products, such as insulin or modified products such as antibody-drug conjugates or PEGylated versions of products, would require additional modules for enzymatic processing, chemical ligation or crystallization; such systems could include de novo synthesis of the key starting materials or active pharmaceutical ingredient as well 29 . Further integration of multiple units may also facilitate blended products of multicomponent vaccines or unique drug combinations tailored for applications for regional use or precision medicine.
MeThodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Filtered (0.2 µm PTFE; Tisch Scientific, North Bend, OH) medical-grade oxygen (Airgas, Radnor, PA) was delivered through a metal sparge ring at the bottom of the vessel. Dissolved oxygen tension was measured using a 225 mm VisiFerm probe (Hamilton, Reno, NV) and controlled using a splitrange proportional-integral (PI) controller, manipulating oxygen sparge rates (at low oxygen uptake rates) or stirrer speed (at high oxygen uptake rates).
A two-level cascade controller was used for temperature control. In the outer loop, vessel temperature was measured using the dissolved oxygen sensor's built in thermocouple and a PI controller was used to set the jacket set point. In the inner loop, the jacket temperature was measured using an embedded thermocouple and used to determine the duty cycle of the resistive heater or chilled 1:1 ethylene glycol:water loop (Julabo USA, Allentown, PA). Disposable gamma-irradiated tubing assemblies were custom-built for the InSCyT system (High Purity New England, Smithfield, RI) to deliver media and collect perfusate. These assemblies were constructed of 1.52 mm i.d. three-stop PharMed BPT peristaltic cassettes, platinum-cured silicone tubing and HDPE carboys, along with appropriate PVDF barbed fittings. Flow into and out of the bioreactor was driven by Ismatec Reglo ICC peristaltic pumps with Asco Scientific three-way pinch valves (Cole-Parmer, Vernon Hills, IL). Clarified perfusate was withdrawn from the bioreactors using two custom modified probes each holding two porous 0.2-µm ceramic membranes (FISP, Flownamics, Madison, WI). Feed bottles were suspended on scales (Mettler Toledo, Columbus, OH) and closed-loop control was used to ensure constant flow. A conducting 3/16-inch grade 2 titanium probe (McMaster-Carr, Robbinsville, NJ), coupled to an Omron Automation 24V AC/DC monitoring relay (Allied Electronics, Fort Worth, TX) was used for level sensing and transmitting, activating the perfusion pump upon liquid contact. The level was maintained through equal media addition and perfusion rates. A periodic backwash was used to prevent membrane fouling.
Bioreactors were sampled automatically using a Seg-Flow 4800 Sampling System, a FlowFraction 400 and Seg-Mod modules (Flownamics, Inc., Madison, WI), and held at 4 °C until further analysis.
Perfusate adjustment module design and operation control. A pH adjustment module (pHAM) was used to adjust the pH of the perfusate before loading onto the first chromatography column. Supernatant was collected in a 1-L surge tank to balance flow rates between the bioreactor and the first column. Custom conductivity-based level sensors enabled automated startup of the downstream process at sufficient volume. Addition of adjustment solution in an in-line mixer (Stamixco, Wollerau, Switzerland) was used to adjust the perfusate pH before the first column. The pH was measured using a custom in-line pH probe (Van London Co., Houston, TX), and a PI controller determined the adjustment rate.
Purification module design and operation control. Up to three productspecific chromatography columns, operated in either bind and step gradient elution or flow-through mode, were used for purification. Flow was provided by a microannular gear pump (mzr-2905; HNP Mikrosysteme, Schwerin, Germany) and a flow sensor (SLI-2000; Sensiron, Zurich, Switzerland) in closed-loop PID control and passed through a debubbler/degasser (9000-1545, Idex Health and Science, Oak Harbor, WA). The columns were operated either independently or in series using multi-port (C65-3180IA; VICI Valco, Houston, TX) and solenoid (100T3MP24-62-5; BioChem Fluidics, Boonton, NJ) valves. Purification processes were operated using a predetermined sequence of steps, controlled either by time or by A 280 measurements (model 280; Spectrum Labs, CA). Purified drug substance eluted from the final chromatography column was directed to the retentate reservoir within the formulation module.
Formulation module design and operation control. A tangential flow filtration system (TFF) (KRIIi; Spectrum Labs, CA) was used to concentrate and/or buffer exchange the eluted drug substance. The system was equipped with WaterSep Discover24 (or Discover12) membranes (5 kDa MWCO, 1.0 mm i.d.) (Marlborough, MA). Automated processing was enabled through custom scripting.
Module integration and automation. Modicon M221 PLCs (Schneider Electric, Andover, MA) were used for the connection of the thermocouple, motors, solenoids, level transmitters, UV transmitters and pH transmitters with the process local area network (LAN). The dissolved oxygen probes and oxygen mass flow controllers were connected to the process LAN via a Modbus to Ethernet endpoint (Sealevel, Liberty, SC), while the peristaltic pump and multi-port valve drives were connected to the process LAN via a RS-232 to Ethernet endpoint (Sealevel, Liberty, SC).
Wonderware (Lake Forest, CA) was used as a human-machine interface (HMI) to the integrated system. Custom scripts were written using Intouch QuickScript (Wonderware, Lake Forest, CA) to implement the USP, pHAM and DSP control loops, recipes, and operating sequences. These scripts were written in house or with assistance from Superior Controls (Seabrook, NH). Wonderware was also used as a data historian, with local download and processing performed using custom scripts in Matlab (MathWorks, Natick, MA).
Production of biologics using the InSCyT system. All numbered buffers referenced below are listed in Supplementary Table 2. All chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Production of hGH using the InSCyT system: first-generation production. Bioreactors were filled with buffered glycerol-complex medium (BMGY) through pleated polyethersulfone 0.2-µm filters (Polycap 36 TC; GE Healthcare, Boston, MA). BMGY and buffered methanol-complex medium (BMMY) were sequentially fed to the reactor for outgrowth and induction, respectively 31 . Sigma A204 anti-foam (A8311; Sigma-Aldrich, St. Louis, MO) was added to BMMY at a concentration of 0.02% v/v. The working volume for all fermentations was 420 mL. Temperature and pH were maintained at 25 °C and 6.5, respectively.
BMGY was fed at 0.5 mL/min for 32 h to accumulate biomass. Dissolved oxygen was maintained at 100%. Mixing was achieved using two Rushton impellers. Perfusate was directed to the waste. After 32 h BMGY was automatically substituted for BMMY and perfusate was directed to the waste for 8 h. Forty hours after inoculation, perfusate was automatically diverted to the pHAM.
A first-generation pHAM was used to adjust the perfusate to pH 5.5 before loading onto the first chromatography column. pH was measured using an in-line pH probe (InLab Reach 425; Mettler Toledo, Columbus, OH) under a recirculation loop. A feedback controller was used to continuously vary the rate of phosphoric acid (500 mM) addition. A magnetic stir bar was used for mixing.
For each cycle of the purification module, 100 column volumes (CV) of adjusted perfusate were loaded onto a 5-mL prepacked multimodal cation exchange (MMCEX) column (CMM HyperCel; Pall Corporation, Port Washington, NY), equilibrated with buffer 1, washed with buffer 2, and eluted with buffer 3. Eluate from column 1 above 15 mAU was flowed through a 1-mL prepacked anion exchange (AEX) column (HyperCel STAR AX; Pall Corporation, Port Washington, NY). Flow-through from column 2 above 15 mAU was collected for formulation. The columns were stripped with buffer 4 and re-equilibrated with buffers 1 and 3, respectively.
Eluate from the final column was dialyzed against buffer 5 using 3.5K MWCO Slide-A-Lyzer G2 dialysis cassettes (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's recommended protocol.
Production of hGH using the InSCyT system: second-generation extended production. The second-generation extended production of hGH was conducted the same as the first-generation production of hGH except for the following changes. BMGY was substituted for rich defined medium 31 containing 4% glycerol and BMMY was substituted for rich defined medium 31 containing 3% methanol. Dissolved oxygen was maintained at 25%. The pHAM described under "Perfusate adjustment module design and operation control" above was used. The adjustment fluid was 100 mM phosphoric acid. 80 CVs of adjusted perfusate (60 CVs for the purification cycle on day 10) was loaded onto the first column. Flow-through from the second column above 15 mAU was directed to the TFF module for formulation.
The formulation module was automatically triggered by the attached process computer at a fixed, regular interval, processing any eluate that had collected in the retentate reservoir. The feed pump was operated at a sufficient rate to maintain 50 mL/min crossflow velocity. Permeation rate was controlled though the use of a backpressure regulator valve set to maintain 30 psi transmembrane pressure. Concentration was performed on the TFF module (concentration factor 2.75) and then diafiltration was performed with buffer 6 (8 diavolumes).
Production of IFNα-2b using the InSCyT system: IFNα-2b process development experiment 1 (PDE 1). Production of IFNα-2b during PDE 1 was conducted the same as the first-generation production of hGH except for the following changes. Reactors were inoculated with an rIFNα-2b-secreting strain. 100 mM citric acid was used to adjust the pH to 5.0 in the pHAM. No recirculation loop was used in the pHAM; the pH was measured in tank by a model F-635 FermProbes (Broadley-James, Irvine, CA).
60 CV of supernatant was loaded onto a 5-mL prepacked MMCEX column (Capto MMC ImpRes; GE Healthcare Bio-Sciences, Pittsburgh, PA), equilibrated with buffer 7, washed with buffer 8 and eluted with buffer 9. Eluate from column 1 above 15 mAU was loaded onto a 5-mL hydrophobic charge induction chromatography (HCIC) column (MEP HyperCel; Pall Corporation, Port Washington, NY), equilibrated with buffer 9, washed with buffer 10 and eluted with buffer 11. Eluate from column 2 above 15 mAU was loaded onto a 5 mL prepacked cation exchange (CEX) column (SP Sepharose High Performance; GE Healthcare Bio-Sciences, Pittsburgh, PA), equilibrated with buffer 11, washed with buffer 12 and eluted with buffer 13. Eluate from column 3 above 10 mAU was collected for formulation. Columns were then stripped with buffer 4 and re-equilibrated at the equilibration conditions given above.
Eluate from the final column was dialyzed against buffer 14 using 3.5K MWCO Slide-A-Lyzer G2 dialysis cassettes (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's recommended protocol.
IFNα-2b process development experiment 2 (PDE 2). Production of IFNα-2b during PDE 2 was conducted the same as production of IFNα-2b during PDE 1 except the elution buffer for the third column was buffer 15.
IFNα-2b process development experiment 3 (PDE 3). Production of IFNα-2b during PDE 3 was conducted the same as the second-generation production of hGH except for the following changes. Reactors were inoculated with an rIFNα-2b-secreting strain. The methanol-containing medium had 1% methanol. Dissolved oxygen was maintained at 40%. Mixing was achieved using one Rushton impeller (top) and one marine impeller (bottom). Perfusate pH was adjusted to 5.0 using 100 mM citric acid in the pHAM.
Purification was the same as in IFNα-2b PDE 2 except all columns were 1 mL and 110 CVs of supernatant were loaded onto the first column.
IFNα-2b process development experiment 4 (PDE 4). Production of IFNα-2b using the InSCyT system during PDE 4 was conducted the same as PDE 3 except for the following changes. Column 1 was eluted with buffer 16. Eluate from column 1 above 15 mAU was flowed through a 1 mL AEX column (HyperCel STAR AX; Pall Corporation, Port Washington, NY). Flow-through from column 2 above 15 mAU was loaded onto a 1 mL prepacked multimodal column (HEA HyperCel; Pall Corporation, Port Washington, NY), equilibrated with buffer 16, washed with buffer 17 and eluted with buffer 18. Eluate from column 3 above 10 mAU was collected for formulation and dialyzed as described in IFNα-2b PDE 1. Columns were then stripped with buffer 4 and re-equilibrated at the equilibration conditions given above.
IFNα-2b process qualification run. Production of IFNα-2b using the InSCyT system during the process qualification run was conducted the same as the second-generation production of hGH except for the following changes. Reactors were inoculated with an rIFNα-2b secreting strain. Upstream samples were not taken between hours 80 and 112 due to failure of the automated sampling system. For yield calculations, the titer during those hours is assumed to be the same as the titer of the previous sample pool (hours 56-78). Perfusate was adjusted to pH 5.0 in the pHAM using 100 mM citric acid.
Purification was the same as in IFNα-2b PDE 2 except 80 CVs of supernatant were loaded onto the first column. Eluate from column 3 above 10 mAU was directed to the TFF for formulation. No concentration was performed. Diafiltration was performed with buffer 19.
Production of G-CSF using the InSCyT system. Production of G-CSF was conducted the same as the second-generation production of hGH except for the following changes. Reactors were inoculated with an rG-CSF secreting strain. 0.1% CHAPs (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate) was added to the medium. Mixing was achieved using one Rushton impeller (top) and one marine impeller (bottom). Perfusate was adjusted to pH 5.0 in the pHAM using 100 mM citric acid .
100 CVs of adjusted perfusate were loaded onto a 5 mL prepacked MMCEX column (Capto MMC ImpRes; GE Healthcare Bio-Sciences, PA), equilibrated with buffer 7, washed with buffer 20 and eluted with buffer 21. Eluate from column 1 above 15 mAU was flowed through a 1 mL prepacked AEX column (HyperCel STAR AX; Pall Corporation, Port Washington, NY). Flow-through from column 2 above 12 mAU was loaded onto a 5 mL HCIC column (MEP HyperCel; Pall Corporation, Port Washington, NY), equilibrated with buffer 21, washed with buffer 22 and eluted with buffer 11. Eluate from column 3 above 12 mAU was directed to the TFF for formulation. Each of the columns was then stripped with buffer 4 and re-equilibrated with the equilibration conditions mentioned above for the first and third column and buffer 21 for the second column. No concentration was performed. Diafiltration was performed with buffer 23.
Analytical methods. Wet cell weight. To determine wet cell weight (g/L), 300 µL of resuspended bioreactor sample was dispensed into a preweighed Spin-X centrifuge tube (Corning, NY) and centrifuged at 15,000g for 10 min in technical triplicate. The mass of the pellet was determined by weight.
SDS-PAGE. SDS-PAGE was carried out under reducing conditions using Novex 12% Tris-Glycine Midi Gels (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's recommended protocol and stained using Instant Blue Protein Stain (Thermo Fisher Scientific, Waltham, MA).
Product-specific enzyme-linked immunosorbent assay (ELISA). Protein concentrations were determined using sandwich ELISA for G-CSF and direct ELISA for IFNα-2b as described elsewhere except for the following changes 32 . Supplementary Table 3 shows the antibodies used. All reagents were added at 100 µL/well instead of 50 µL/well. Wash buffer was PBS, 0.05% Tween. Blocking buffer was PBS, 0.05% Tween, 0.25% BSA, and blocking steps were incubated at 37 °C for 1 h. Detection enzyme was incubated for 30 min. Substrate solution was ABTS (Thermo Fisher Scientific, Waltham, MA) and was incubated for 20 min. Stop solution was 0.1 M citric acid, 0.01% sodium azide. Plates were analyzed for absorbance at 410 nm/540 nm using a Tecan Infinite M200 Pro plate reader.
Process-related impurity analysis. Samples were analyzed for host-cell protein content using the Pichia pastoris 2nd Generation HCP ELISA kit from Cygnus Technologies (Southport, NC) according to the manufacturer's recommended protocol. Samples were analyzed for residual host-cell DNA using the resDNASEQ Quantitative Pichia pastoris DNA kit (Applied Biosystems, Foster City, CA) according to the manufacturer's recommended protocol. DNA was first extracted from each sample using the PrepSEQ Residual DNA Sample Preparation kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's recommended protocol. qPCR reactions were performed using a Roche LightCycler 480II equipped with LightCycler software release 1.5.0SP4 (Roche Molecular Systems, Inc., Indianapolis, IN). Analysis was performed using the built-in software as recommended in the manufacturer's protocol. The experiments presented in this work were representative of greater than 35 independent operational replicates performed under similar conditions to determine optimal process parameters for production and their impact on quality attributes of proteins. Sample sizes were not predetermined. Instead, replicate experiments (min n=3) were initially performed for each condition or process.
Variations or quality deviations were noted. Process conditions were adjusted accordingly and experiments were performed again in replicate to confirm new conditions. Iterations were performed until variation and quality was acceptable. Sample size for non-clinical studies was selected to be the minimum number of animals required to obtain statistically significant results.
Data exclusions
Describe any data exclusions. Technical outliers were excluded from the cell-based potency assays for biologic activity of hGH (as determined by a third-party CRO Bioassay GmbH based on their Quality Assurance protocols for data generated in these assays and described in Methods). No data were excluded from analysis in other experiments reported.
Replication
Describe whether the experimental findings were reliably reproduced.
The production and characterization of G-CSF, IFNalpha-2b, and hGH presented in this work were representative of more than 35 independent operational replicates performed with similar parameters to map optimal production conditions. Quality attributes of materials were consistent with expectations (for example, higher dissolved oxygen led to higher levels of oxidation of protein). Materials produced in this work were regularly generated in triplicate using three independent automated production systems.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For the non-clinical studies presented in this work randomization was performed to allocate animals into experimental groups using Research Randomizer software, version 4.0.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For the non-clinical studies presented in this work blinding was not performed. The study employed methodology to minimize uncertainty and to control bias for data collection and analysis, however, which included but was not limited to: concurrent control data, system suitability assessment, randomization, and method controls such as blanks and replicates.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Wonderware 2014 R2 was used as a human-machine interface to the integrated system and as a data historian. GraphPad Prism v7 was used to plot and analyze all data in the manuscript and supplemental material, except for the following. MATLAB 2017a was used for plotting and analysis of the fermentograms and UV traces presented. LightCycler software release 1.5.0SP4 was used for qPCR analysis. Empower 3 was used for control in chromatographic analyses. Thermo BioPharmaFinder 2.0 was used for analysis of LCMS data. Provantis 9.3.1 and WinNonlin 6.3 was used for analysis in the non clinical studies.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
